These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 27558398)
1. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis? Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP; Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398 [TBL] [Abstract][Full Text] [Related]
2. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315 [TBL] [Abstract][Full Text] [Related]
3. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119 [TBL] [Abstract][Full Text] [Related]
4. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297 [TBL] [Abstract][Full Text] [Related]
5. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial. Sode J; Krintel SB; Carlsen AL; Hetland ML; Johansen JS; Hørslev-Petersen K; Stengaard-Pedersen K; Ellingsen T; Burton M; Junker P; Østergaard M; Heegaard NHH J Rheumatol; 2018 Jan; 45(1):53-61. PubMed ID: 29142030 [TBL] [Abstract][Full Text] [Related]
6. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients. Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553 [TBL] [Abstract][Full Text] [Related]
7. Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis. Cuppen BV; Fu J; van Wietmarschen HA; Harms AC; Koval S; Marijnissen AC; Peeters JJ; Bijlsma JW; Tekstra J; van Laar JM; Hankemeier T; Lafeber FP; van der Greef J; PLoS One; 2016; 11(9):e0163087. PubMed ID: 27631111 [TBL] [Abstract][Full Text] [Related]
8. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516 [TBL] [Abstract][Full Text] [Related]
9. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis. Shi R; Chen M; Litifu B Mod Rheumatol; 2018 Jan; 28(1):126-132. PubMed ID: 28657833 [TBL] [Abstract][Full Text] [Related]
10. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study. Einarsson JT; Geborek P; Saxne T; Kapetanovic MC J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762 [TBL] [Abstract][Full Text] [Related]
11. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study. Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921 [TBL] [Abstract][Full Text] [Related]
12. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis. Luque-Tévar M; Perez-Sanchez C; Patiño-Trives AM; Barbarroja N; Arias de la Rosa I; Abalos-Aguilera MC; Marin-Sanz JA; Ruiz-Vilchez D; Ortega-Castro R; Font P; Lopez-Medina C; Romero-Gomez M; Rodriguez-Escalera C; Perez-Venegas J; Ruiz-Montesinos MD; Dominguez C; Romero-Barco C; Fernandez-Nebro A; Mena-Vazquez N; Marenco JL; Uceda-Montañez J; Toledo-Coello MD; Aguirre MA; Escudero-Contreras A; Collantes-Estevez E; Lopez-Pedrera C Front Immunol; 2021; 12():631662. PubMed ID: 33833756 [No Abstract] [Full Text] [Related]
13. Correlation of microRNA expression profile with clinical response to tumor necrosis factor inhibitor in treating rheumatoid arthritis patients: A prospective cohort study. Liu Y; Han Y; Qu H; Fang J; Ye M; Yin W J Clin Lab Anal; 2019 Sep; 33(7):e22953. PubMed ID: 31245894 [TBL] [Abstract][Full Text] [Related]
14. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Krintel SB; Dehlendorff C; Hetland ML; Hørslev-Petersen K; Andersen KK; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard HM; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Jørgensen A; Raun J; Ammitzbøll CG; Østergaard M; Stengaard-Pedersen K; Johansen JS Pharmacogenomics J; 2016 Apr; 16(2):141-6. PubMed ID: 25939484 [TBL] [Abstract][Full Text] [Related]
15. Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. Smith SL; Eyre S; Yarwood A; Hyrich K; Morgan AW; Wilson AG; Isaacs J; ; Plant D; Barton A Arthritis Res Ther; 2015 Dec; 17():359. PubMed ID: 26667261 [TBL] [Abstract][Full Text] [Related]
16. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402 [TBL] [Abstract][Full Text] [Related]
17. Low Percentage of Signal Regulatory Protein α/β Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C Front Immunol; 2018; 9():2865. PubMed ID: 30568660 [TBL] [Abstract][Full Text] [Related]
18. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Wampler Muskardin T; Vashisht P; Dorschner JM; Jensen MA; Chrabot BS; Kern M; Curtis JR; Danila MI; Cofield SS; Shadick N; Nigrovic PA; St Clair EW; Bingham CO; Furie R; Robinson W; Genovese M; Striebich CC; O'Dell JR; Thiele GM; Moreland LW; Levesque M; Bridges SL; Gregersen PK; Niewold TB Ann Rheum Dis; 2016 Oct; 75(10):1757-62. PubMed ID: 26546586 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. Hruskova V; Jandova R; Vernerova L; Mann H; Pecha O; Prajzlerova K; Pavelka K; Vencovsky J; Filkova M; Senolt L Arthritis Res Ther; 2016 Jun; 18(1):124. PubMed ID: 27255643 [TBL] [Abstract][Full Text] [Related]
20. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]